Table 1

Patient characteristics

CTTTICI
SARS-CoV-2 negative
n=37
SARS-CoV-2 positive
n=13
Overall
n=50
SARS-CoV-2 negative
n=60
SARS-CoV-2 positive
n=24
Overall
n=84
SARS-CoV-2 negative
n=107
SARS-CoV-2 positive
n=52
Overall
n=159
Age
Mean (SD)66.3 (11.7)63.2 (14.2)65.5 (12.4)62.3 (13.7)61.6 (12.8)62.1 (13.4)66.3 (12.5)66.9 (11.3)66.5 (12.1)
Median (Q1–Q3)69.0 (61.0–75.0)65.0 (58.0–73.0)67.5 (58.0–75.0)65.0 (54.5–72.5)63.5 (53.5–70.0)63.5 (54.5–71.5)69.0 (59.0–75.0)68.0 (62.0–73.5)69.0 (60.0–75.0)
Min–Max26.0–84.026.0–81.026.0–84.028.0–88.031.0–84.028.0–88.020.0–89.039.0–86.020.0–89.0
Sex
Female12 (32.4)4 (30.8)16 (32.0)33 (55.0)10 (41.7)43 (51.2)36 (33.6)16 (30.8)52 (32.7)
Male25 (67.6)9 (69.2)34 (68.0)27 (45.0)14 (58.3)41 (48.8)71 (66.4)36 (69.2)107 (67.3)
Number of subjects with at least one comorbidity other than cancer25 (67.6)8 (61.5)33 (66.0)32 (53.3)11 (45.8)43 (51.2)60 (56.1)28 (53.8)88 (55.3)
Description of comorbidities:
Number of comorbidities (n%)
One comorbidity17 (68.0)6 (75.0)23 (69.7)24 (75.0)7 (63.6)31 (72.1)39 (65.0)21 (75.0)60 (68.2)
More than one comorbidity8 (32.0)2 (25.0)10 (30.3)8 (25.0)4 (36.4)12 (27.9)21 (35.0)7 (25.0)28 (31.8)
Number of patients with cardiac disease17 (68.0)5 (62.5)22 (66.7)24 (75.0)8 (72.7)32 (74.4)45 (75.0)26 (92.9)71 (80.7)
Number of patients with pulmonary disease6 (24.0)4 (50.0)10 (30.3)8 (25.0)4 (36.4)12 (27.9)22 (36.7)2 (7.1)24 (27.3)
Number of patients with chronic kidney disease2 (8.0)1 (12.5)3 (9.1)5 (15.6)0 (0.0)5 (11.6)5 (8.3)2 (7.1)7 (8.0)
Number of patients with diabetes7 (28.0)1 (12.5)8 (24.2)2 (6.3)3 (27.3)5 (11.6)16 (26.7)6 (21.4)22 (25.0)
Number of patients with underlying immunodeficiency2 (8.0)0 (0.0)2 (6.1)2 (6.3)0 (0.0)2 (4.7)0 (0.0)0 (0.0)0 (0.0)
Cancer details
Cancer type
Melanoma0 (0.0)0 (0.0)0 (0.0)34 (56.7)18 (75.0)52 (61.9)54 (50.5)37 (71.2)91 (57.2)
NSCLC20 (54.1)9 (69.2)29 (58.0)15 (25.0)3 (12.5)18 (21.4)43 (40.2)10 (19.2)53 (33.3)
RCC1 (2.7)2 (15.4)3 (6.0)9 (15.0)3 (12.5)12 (14.3)7 (6.5)5 (9.6)12 (7.5)
Other16 (43.2)2 (15.4)18 (36.0)2 (3.3)0 (0.0)2 (2.4)3 (2.8)0 (0.0)3 (1.9)
Cancer stage (AJCC v8)
III6 (16.2)4 (30.8)10 (20.0)11 (18.3)4 (16.7)15 (17.9)25 (23.4)15 (28.8)40 (25.2)
IV31 (83.8)9 (69.2)40 (80.0)49 (81.7)20 (83.3)69 (82.1)82 (76.6)37 (71.2)119 (74.8)
  • .AJCC, american joint committee on cancer; CT, chemotherapy; ICI, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; Q1, first quartile; Q3, third quartile; RCC, renal cell carcinoma; TT, targeted therapy.